Tesamorelin dosage: reported doses and schedule
A peptide approved for deep abdominal fat in adults with HIV lipodystrophy.
Also called: TH9507, TH-9507, Egrifta, Egrifta SV, Egrifta WR.
GHRH analogues · Growth hormone-releasing hormone receptor agonist · Evidence: Approved drug.
Typical reported dose: 1.28 mg once a day (Egrifta WR)
- Egrifta WR: 1.28 mg: 1.28 mg subcutaneously once daily once daily, under the skin. Drug label. Studied in: Adults with HIV-associated lipodystrophy and excess abdominal fat. (source)
- Egrifta SV: 1.4 mg: 1.4 mg, 0.35 mL of the reconstituted solution, injected subcutaneously once daily once daily, under the skin. Drug label. Studied in: Adults with HIV-associated lipodystrophy and excess abdominal fat. (source)
- Original Egrifta: historical 2 mg: 2 mg injected subcutaneously once daily once daily, under the skin. Drug label. Studied in: Adults with HIV-associated lipodystrophy and excess abdominal fat. (source)
- Pivotal HIV regimen: Original tesamorelin 2 mg SC daily once daily, under the skin. Studied in a trial. Studied in: Adults with HIV-associated lipodystrophy and excess abdominal fat. (source)
- 1 mg dose-finding arm: 1 mg SC once daily once daily, under the skin. Studied in a trial. Studied in: Adults with HIV-associated lipodystrophy and excess abdominal fat. (source)
- 2 mg dose-finding arm: 2 mg SC once daily once daily, under the skin. Studied in a trial. Studied in: Adults with HIV-associated lipodystrophy and excess abdominal fat. (source)
Highest studied: A 3 mg SC daily arm exposed only one COPD participant; the main efficacy trials used 2 mg daily.; Early FDA-reviewed study used 2 mg SC twice daily for 14 days..
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to Tesamorelin
- CJC-1295 without DAC: A peptide intended to trigger growth hormone release, with no human dosing study found.
- Sermorelin: An experimental short-acting peptide that triggers growth hormone release, with limited evidence of adult benefits.
- CJC-1295 with DAC: An experimental long-acting peptide that triggers growth hormone release, with no proven muscle or recovery benefit.
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- Ipamorelin: An experimental peptide that triggers growth hormone release.
Sources
- Compounding and the FDA: Questions and Answers, FDA · FDA · 2026
- Purple Book Search, FDA · 2026
- Search results summary, Health Canada · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- EGRIFTA WR (tesamorelin) for injection, for subcutaneous use, U.S. Food and Drug Administration · FDA · 2025
- Supply unlicensed medicinal products (specials), MHRA · 2025
- EGRIFTA SV (tesamorelin) for injection, for subcutaneous use, 2024
- Egrifta, 2012
- EGRIFTA (tesamorelin for injection) for Subcutaneous Use, 2010
- EGRIFTA: Chemistry Review, NDA 22-505, 2010
- EGRIFTA: Clinical Pharmacology and Biopharmaceutics Review, NDA 22-505, 2010
- EGRIFTA: Clinical Review, NDA 22-505, 2010
- Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials., Badran AS et al. · Obesity research & clinical practice · 2026
- Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists., Beach R et al. · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.